Jounce Therapeutics Inc (NASDAQ:JNCE) has received an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price target of $30.00 for the company and are predicting that the company will post ($0.59) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Jounce Therapeutics an industry rank of 108 out of 265 based on the ratings given to its competitors.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Jounce Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Robert W. Baird reiterated an “outperform” rating and set a $30.00 price objective on shares of Jounce Therapeutics in a research note on Monday, September 18th. Finally, J P Morgan Chase & Co set a $28.00 price objective on shares of Jounce Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th.

Large investors have recently made changes to their positions in the business. Macquarie Group Ltd. acquired a new stake in shares of Jounce Therapeutics in the third quarter valued at approximately $124,000. American International Group Inc. increased its stake in shares of Jounce Therapeutics by 132.2% in the third quarter. American International Group Inc. now owns 9,559 shares of the company’s stock valued at $149,000 after purchasing an additional 5,442 shares during the period. TIAA CREF Investment Management LLC acquired a new stake in shares of Jounce Therapeutics in the first quarter valued at approximately $229,000. Teachers Advisors LLC increased its stake in shares of Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after purchasing an additional 2,347 shares during the period. Finally, Ark Investment Management LLC increased its stake in shares of Jounce Therapeutics by 558.9% in the second quarter. Ark Investment Management LLC now owns 11,932 shares of the company’s stock valued at $167,000 after purchasing an additional 10,121 shares during the period. Institutional investors own 47.55% of the company’s stock.

Jounce Therapeutics (NASDAQ:JNCE) traded down $0.29 on Wednesday, reaching $12.52. 834,859 shares of the company traded hands, compared to its average volume of 145,879. Jounce Therapeutics has a 52-week low of $11.05 and a 52-week high of $29.29.

Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.12. The firm had revenue of $18.10 million for the quarter, compared to analyst estimates of $20.00 million. Jounce Therapeutics had a negative net margin of 2.03% and a negative return on equity of 1.39%. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. analysts expect that Jounce Therapeutics will post -0.86 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/16/analysts-set-30-00-price-target-for-jounce-therapeutics-inc-jnce.html.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.